biostudies-literatureTorres MInstituto de Salud Carlos IIINIAID NIH HHSEspaña Ministerio de Ciencia e Innovación112965https://www.ebi.ac.uk/biostudies/studies/S-EPMC9008199biostudies-literatureUnknown150Main cause of severe illness and death in COVID-19 patients appears to be an excessive but ineffectual inflammatory immune response that may cause severe acute respiratory distress syndrome (ARDS). Vitamin D may favour an anti-inflammatory environment and improve cytotoxic response against some infectious diseases. A multicenter, single-blind, prospective, randomized clinical trial was approved in patients with COVID-19 pneumonia and levels of 25-hydroxyvitamin D (25(OH)D) of 14.8 ng/ml (SD: 6.18) to test antiviral efficacy, tolerance and safety of 10,000 IU/day of cholecalciferol (vitamin D₃) for 14 days, in comparison with 2000 IU/day. After supplementation, mean serum 25(OH)D levels increased to 19 ng/ml on average in 2000 IU/day versus 29 ng/ml in 10,000 IU/day group (p < 0.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieChanges in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D.PMC9008199R01 AI143567Mateos ETaboada-Martinez MLPatricia Fernandez Fernandez CPardo Guimera VJose Martinez Martin EContributing members of the Multidisciplinary Group of Study of COVID-19 (in alphabetical order)Garcia Lacalle CMultidisciplinary Group of Study of COVID-19 (MGS-COVID)Cascajero Diaz ACarrillo Blanco GMartin Sagarra ORenuncio Garcia DRamos-Martin FTorres Perea RJavier Martinez Simon JSanz-Moreno JTeresa Chica Burguillo MDiez Vinas VArevalo Camacho SSanz Moreno JLopez-Wolf DRodriguez-Mora SFernandez Mondelo YLucena Campillo ALuisa Pinillos Pardo MVelasco Arribas MValencia La Rosa JCorrochano Garcia ATorres MAlonso-Menchen DBlanca Lopez NFonseca Aizpuri EGarcia-Perez JRoger Revilla AMatarranz Del Amo MCasado GLopez-Huertas MRHelguera Amezua CGomez-Alvarez Dominguez MNovella-Mena MVigon LRyan-Murua PAngeles Rodriguez Davila MSampablo Valverde LCanamares Orbis IRamirez Fuentes FACervero MJose Hidalgo Correas FVillanueva Fernandez-Ardavin ACoiras MCorredera Garcia SAvila Calzada CAntonio Barbado Albaladejo JfalseChanges in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D.Main cause of severe illness and death in COVID-19 patients appears to be an excessive but ineffectual inflammatory immune response that may cause severe acute respiratory distress syndrome (ARDS). Vitamin D may favour an anti-inflammatory environment and improve cytotoxic response against some infectious diseases. A multicenter, single-blind, prospective, randomized clinical trial was approved in patients with COVID-19 pneumonia and levels of 25-hydroxyvitamin D (25(OH)D) of 14.8 ng/ml (SD: 6.18) to test antiviral efficacy, tolerance and safety of 10,000 IU/day of cholecalciferol (vitamin D₃) for 14 days, in comparison with 2000 IU/day. After supplementation, mean serum 25(OH)D levels increased to 19 ng/ml on average in 2000 IU/day versus 29 ng/ml in 10,000 IU/day group (p < 0.2022-01-01T00:00:00Z2022 Jun2025-05-18T10:52:48.89Z2024-10-17T18:32:02.461ZS-EPMC90081993546858010.1016/j.biopha.2022.112965